References for: association

Full identifier: http://purl.org/np/RASJaMbKa-cU8ftUssfy-9ujTrcHUr2ARWXqKWqyl3_pw#association

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-25T12:46:33.571Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-25T12:46:33.571Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-25T12:46:33.571Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-25T12:46:33.571Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-25T12:46:33.571Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-25T12:46:33.571Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-25T12:46:33.571Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
The most commonly reported diagnosis treated was Major Depressive Disorder (72.2%), followed by Bipolar Disorder (15.1%), and Posttraumatic Stress Disorder (5.7%). Most providers (87.7%) reported administering ketamine via an intravenous route, with a minority reporting using an oral (22.8%) or an intranasal (19.3%) formulation.
0000-0002-7641-6446
2021-05-25T12:46:33.571Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-25T12:46:33.571Z
links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion
association
0000-0002-7641-6446
2021-05-25T12:46:33.571Z